Investors

News Releases

Date Title  
Toggle Summary POZEN and Tribute Announce Effectiveness of Registration Statement on Form S-4
    POZEN Schedules Stockholder Meeting for December 10, 2015     Tribute Schedules Shareholder Meeting for December 9, 2015     CHAPEL HILL, N.C. & MILTON, Ontario--November 6, 2015--POZEN Inc. ("POZEN")    (POZN) and Tribute Pharmaceuticals Canada Inc.
Toggle Summary POZEN And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals
- US$350 Million Capital Commitment from Deerfield-Led Syndicate- -Canada Domicile Provides Similar Competitive Structure and Benefits to Ireland - -Previously Scheduled Shareholder Meetings of POZEN and Tribute to be Rescheduled- CHAPEL HILL, N.C. and MILTON, Ontario , Dec.
Toggle Summary POZEN and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals
     -Canada Domicile Provides Similar Competitive    Structure and Benefits to Ireland-     -Previously Scheduled Shareholder Meetings of    POZEN and Tribute to be Rescheduled-     CHAPEL HILL, NORTH CAROLINA and MILTON, ONTARIO -- (Marketwired) -- 12/07/15 --    POZEN Inc.
Toggle Summary POZEN And Tribute Provide Update On Pending Combination Transactions
-POZEN and Tribute Evaluating Canadian Domicile for Aralez Pharmaceuticals- CHAPEL HILL, NORTH CAROLINA and MILTON, ONTARIO -- ( Marketwired ) -- 11/23/15 -- POZEN Inc. ("POZEN") (NASDAQ:POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute") (TSX VENTURE:TRX) (OTCQX:TBUFF) today provided an
Toggle Summary POZEN Announces August 10th Webcast of Second Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jul. 27, 2015-- POZEN Inc. (NASDAQ: POZN) announced today that it plans to release second quarter 2015 results on August 10, 2015 , before the market opens. The announcement will be followed by a live webcast at 2:00 p.m.
Toggle Summary POZEN Announces Effectiveness Of Aralez Registration Statement On Form S-4 And Provides Update On Key Milestones For 2016
- POZEN schedules stockholder meeting for February 2 , 2016-  -Plan to re-file YOSPRALA™ New Drug Application early in the second quarter; Approval and launch targeted in fourth quarter-  CHAPEL HILL, N.C. , Dec. 28, 2015 /PRNewswire/ --   POZEN Inc.
Toggle Summary POZEN Announces Issuance of VIMOVO® Related Patent by the United States Patent and Trademark Office
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Feb. 4, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled “Method for Treating a
Toggle Summary POZEN Announces Key Leadership Additions
Three New Executives, Each Bring Decades of Experience Working at High Growth Pharmaceutical Companies New Executives Will Also Serve on Leadership Team of Aralez Pharmaceuticals , Following Completion of Merger with Tribute CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 22, 2015-- POZEN Inc.
Toggle Summary POZEN Announces March 9th Webcast of Fourth Quarter and Year End 2014 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Mar. 4, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release fourth quarter and year end 2014 results on March 9, 2015 , before the market opens.
Toggle Summary POZEN Announces May 8th Webcast of First Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--May 4, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2015 results on May 8, 2015 , before the market opens.

Copyright West LLC. Minimum 15 minutes delayed.